Drug Profile
AL 721
Alternative Names: AltrigenLatest Information Update: 30 Sep 2022
Price :
$50
*
At a glance
- Originator Ethigen Corporation
- Developer Ethigen Corporation; Packaging Coordinators Inc; Polagus
- Class Antivirals
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cervical cancer; Cystic fibrosis; HIV infections
Most Recent Events
- 02 Feb 2001 Profile reviewed but no significant changes made
- 20 Nov 2000 Discontinued-II for HIV infections treatment in United Kingdom (PO)
- 03 Jun 1997 No-Development-Reported for Cervical cancer (Unknown route)